JP2019510733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510733A5 JP2019510733A5 JP2018530560A JP2018530560A JP2019510733A5 JP 2019510733 A5 JP2019510733 A5 JP 2019510733A5 JP 2018530560 A JP2018530560 A JP 2018530560A JP 2018530560 A JP2018530560 A JP 2018530560A JP 2019510733 A5 JP2019510733 A5 JP 2019510733A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 230000006044 T cell activation Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 102000043321 human CTLA4 Human genes 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021049294A JP2021100957A (ja) | 2015-12-15 | 2021-03-23 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2022096901A JP7286845B2 (ja) | 2015-12-15 | 2022-06-15 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267735P | 2015-12-15 | 2015-12-15 | |
| US62/267,735 | 2015-12-15 | ||
| US201662309169P | 2016-03-16 | 2016-03-16 | |
| US62/309,169 | 2016-03-16 | ||
| US201662359036P | 2016-07-06 | 2016-07-06 | |
| US62/359,036 | 2016-07-06 | ||
| PCT/US2016/066698 WO2017106372A1 (en) | 2015-12-15 | 2016-12-14 | Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049294A Division JP2021100957A (ja) | 2015-12-15 | 2021-03-23 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510733A JP2019510733A (ja) | 2019-04-18 |
| JP2019510733A5 true JP2019510733A5 (OSRAM) | 2020-01-30 |
| JP6858779B2 JP6858779B2 (ja) | 2021-04-14 |
Family
ID=59057509
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530560A Active JP6858779B2 (ja) | 2015-12-15 | 2016-12-14 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2021049294A Pending JP2021100957A (ja) | 2015-12-15 | 2021-03-23 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2022096901A Active JP7286845B2 (ja) | 2015-12-15 | 2022-06-15 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2025130097A Pending JP2025160458A (ja) | 2015-12-15 | 2025-08-04 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049294A Pending JP2021100957A (ja) | 2015-12-15 | 2021-03-23 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2022096901A Active JP7286845B2 (ja) | 2015-12-15 | 2022-06-15 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2025130097A Pending JP2025160458A (ja) | 2015-12-15 | 2025-08-04 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10618960B2 (OSRAM) |
| EP (2) | EP3389699B1 (OSRAM) |
| JP (4) | JP6858779B2 (OSRAM) |
| KR (2) | KR20250108763A (OSRAM) |
| CN (2) | CN116063492A (OSRAM) |
| AU (2) | AU2016370648B2 (OSRAM) |
| BR (1) | BR112018012113A2 (OSRAM) |
| CA (1) | CA3006984C (OSRAM) |
| DK (1) | DK3389699T5 (OSRAM) |
| ES (1) | ES2979210T3 (OSRAM) |
| FI (1) | FI3389699T3 (OSRAM) |
| HR (1) | HRP20240719T1 (OSRAM) |
| HU (1) | HUE066907T2 (OSRAM) |
| IL (3) | IL259988B2 (OSRAM) |
| LT (1) | LT3389699T (OSRAM) |
| MX (3) | MX2018006925A (OSRAM) |
| MY (1) | MY186974A (OSRAM) |
| PL (1) | PL3389699T3 (OSRAM) |
| PT (1) | PT3389699T (OSRAM) |
| RS (1) | RS65703B1 (OSRAM) |
| SG (1) | SG11201804969PA (OSRAM) |
| SI (1) | SI3389699T1 (OSRAM) |
| SM (1) | SMT202400211T1 (OSRAM) |
| TW (1) | TWI739781B (OSRAM) |
| WO (1) | WO2017106372A1 (OSRAM) |
| ZA (1) | ZA201804077B (OSRAM) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3303394T1 (sl) | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
| EP3515489B1 (en) * | 2016-09-19 | 2025-11-05 | OncoC4, Inc. | Cd80 and cd86 binding protein compositions and uses thereof |
| IL266918B2 (en) | 2016-12-07 | 2024-03-01 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019094637A1 (en) * | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
| US12129299B2 (en) | 2018-02-02 | 2024-10-29 | OncoC4, Inc. | Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects |
| WO2019148444A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| SG11202007018QA (en) * | 2018-02-02 | 2020-08-28 | Oncoimmune Inc | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy |
| CN115991787A (zh) | 2018-06-05 | 2023-04-21 | 江苏康宁杰瑞生物制药有限公司 | 二聚体及其用途 |
| EP3617230A1 (en) * | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| CN119930820A (zh) * | 2018-12-27 | 2025-05-06 | 吉加根公司 | 抗ctla-4结合蛋白及其使用方法 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| KR20220166795A (ko) * | 2020-04-13 | 2022-12-19 | 바이오션, 인코포레이티드 | Ctla4에 결합하는 항체 및 이의 용도 |
| WO2021220251A1 (en) | 2020-05-01 | 2021-11-04 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022117572A2 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | An ltbr agonist in combination therapy against cancer |
| WO2022169269A1 (ko) * | 2021-02-03 | 2022-08-11 | 주식회사 유틸렉스 | 항 ctla-4 항체 및 이의 용도 |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| WO2022214653A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
| JP7345889B2 (ja) * | 2021-06-17 | 2023-09-19 | 株式会社ニューギン | 遊技機 |
| EP4392156A4 (en) * | 2021-10-08 | 2025-06-25 | Kashiv Biosciences, LLC | Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| CA3234491A1 (en) * | 2021-10-08 | 2023-04-13 | Kashiv Biosciences, Llc | Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| MX2024004429A (es) | 2021-10-29 | 2024-05-06 | Oncoc4 Inc | Regimenes de dosificacion del anticuerpo anti-ctla-4. |
| EP4431528A1 (en) * | 2021-10-29 | 2024-09-18 | Longbio Pharma (Suzhou) Co., Ltd. | Isolated antigen binding protein and use thereof |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| CN119947752A (zh) | 2022-09-16 | 2025-05-06 | 昂科医药 | 抗ctla-4抗体用于治疗腺样囊性癌的用途 |
| CN120981564A (zh) | 2023-03-17 | 2025-11-18 | 圭尔医疗有限公司 | 调节性t细胞疗法 |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024227176A1 (en) | 2023-04-28 | 2024-10-31 | OncoC4, Inc. | Combinations of anti-ctla-4 antibodies and anti-pd-1 antibodies and therapeutic uses thereof |
| WO2024254403A2 (en) * | 2023-06-09 | 2024-12-12 | The Regents Of The University Of California | Methods for identifying and correcting tumor humoral immune dysfunction |
| WO2025133186A1 (en) | 2023-12-22 | 2025-06-26 | OncoC4, Inc. | Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent |
| WO2025201659A1 (en) | 2024-03-28 | 2025-10-02 | BioNTech SE | Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DK1210428T3 (en) | 1999-08-23 | 2015-06-15 | Dana Farber Cancer Inst Inc | PD-1, a receptor for B7-4 AND USE THEREOF |
| IL148021A0 (en) | 1999-08-23 | 2002-09-12 | Dana Farber Cancer Inst Inc | Novel b7-4 molecules and uses therefor |
| US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| PT1234031T (pt) | 1999-11-30 | 2017-06-26 | Mayo Foundation | B7-h1, uma nova molécula imunoregulatória |
| US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| AU2002258941A1 (en) | 2001-04-20 | 2002-11-05 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| EP1793857A4 (en) * | 2004-09-08 | 2008-09-03 | Univ Ohio State Res Found | COMBINED THERAPY USING ANTI-CTLA4 ANTI-4-1BB ANTIBODIES |
| EP1793858A4 (en) * | 2004-09-08 | 2008-12-10 | Univ Ohio State Res Found | HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT |
| CN104104517B (zh) | 2004-10-15 | 2017-11-07 | 弗里塞恩公司 | 一次性密码验证的方法和系统 |
| CN101146826A (zh) | 2005-01-24 | 2008-03-19 | 得克萨斯大学体系董事会 | 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途 |
| EP2418278A3 (en) * | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US8062852B2 (en) | 2007-10-01 | 2011-11-22 | The Children's Hospital And Regional Medical Center | Detection and treatment of autoimmune disorders |
| CN101628940B (zh) * | 2008-07-15 | 2011-11-23 | 中国科学院生物物理研究所 | 一种单克隆抗体及其应用 |
| GB0903325D0 (en) * | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2013142796A2 (en) * | 2012-03-23 | 2013-09-26 | Bristol-Myers Squibb Company | Methods of treatments using ctla4 antibodies |
| CN104968364A (zh) | 2012-12-03 | 2015-10-07 | 百时美施贵宝公司 | 强化免疫调变性Fc融合蛋白的抗癌活性 |
| US20160145355A1 (en) * | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| CN104292334B (zh) * | 2014-04-25 | 2018-11-27 | 河南省健康伟业生物医药研究股份有限公司 | 一种全人源抗ctla-4单克隆抗体、制备方法及应用 |
| EP3515489B1 (en) | 2016-09-19 | 2025-11-05 | OncoC4, Inc. | Cd80 and cd86 binding protein compositions and uses thereof |
-
2016
- 2016-12-14 SG SG11201804969PA patent/SG11201804969PA/en unknown
- 2016-12-14 SM SM20240211T patent/SMT202400211T1/it unknown
- 2016-12-14 KR KR1020257022200A patent/KR20250108763A/ko active Pending
- 2016-12-14 PT PT168766129T patent/PT3389699T/pt unknown
- 2016-12-14 BR BR112018012113A patent/BR112018012113A2/pt active Search and Examination
- 2016-12-14 CA CA3006984A patent/CA3006984C/en active Active
- 2016-12-14 IL IL259988A patent/IL259988B2/en unknown
- 2016-12-14 JP JP2018530560A patent/JP6858779B2/ja active Active
- 2016-12-14 WO PCT/US2016/066698 patent/WO2017106372A1/en not_active Ceased
- 2016-12-14 EP EP16876612.9A patent/EP3389699B1/en active Active
- 2016-12-14 RS RS20240735A patent/RS65703B1/sr unknown
- 2016-12-14 CN CN202210802423.XA patent/CN116063492A/zh active Pending
- 2016-12-14 IL IL310404A patent/IL310404A/en unknown
- 2016-12-14 KR KR1020187017368A patent/KR102830926B1/ko active Active
- 2016-12-14 PL PL16876612.9T patent/PL3389699T3/pl unknown
- 2016-12-14 MY MYPI2018000904A patent/MY186974A/en unknown
- 2016-12-14 HU HUE16876612A patent/HUE066907T2/hu unknown
- 2016-12-14 ES ES16876612T patent/ES2979210T3/es active Active
- 2016-12-14 DK DK16876612.9T patent/DK3389699T5/da active
- 2016-12-14 LT LTEPPCT/US2016/066698T patent/LT3389699T/lt unknown
- 2016-12-14 CN CN201680073425.2A patent/CN108430499B/zh active Active
- 2016-12-14 FI FIEP16876612.9T patent/FI3389699T3/fi active
- 2016-12-14 SI SI201631826T patent/SI3389699T1/sl unknown
- 2016-12-14 IL IL296354A patent/IL296354B2/en unknown
- 2016-12-14 MX MX2018006925A patent/MX2018006925A/es unknown
- 2016-12-14 EP EP24164173.7A patent/EP4374926A3/en active Pending
- 2016-12-14 US US16/062,350 patent/US10618960B2/en active Active
- 2016-12-14 HR HRP20240719TT patent/HRP20240719T1/hr unknown
- 2016-12-14 AU AU2016370648A patent/AU2016370648B2/en active Active
- 2016-12-15 TW TW105141656A patent/TWI739781B/zh active
-
2018
- 2018-06-07 MX MX2025001302A patent/MX2025001302A/es unknown
- 2018-06-07 MX MX2025001300A patent/MX2025001300A/es unknown
- 2018-06-18 ZA ZA2018/04077A patent/ZA201804077B/en unknown
-
2020
- 2020-02-27 US US16/803,972 patent/US11629188B2/en active Active
-
2021
- 2021-03-23 JP JP2021049294A patent/JP2021100957A/ja active Pending
-
2022
- 2022-06-15 JP JP2022096901A patent/JP7286845B2/ja active Active
-
2023
- 2023-03-22 US US18/188,098 patent/US12473362B2/en active Active
- 2023-05-19 AU AU2023203169A patent/AU2023203169B2/en active Active
-
2025
- 2025-08-04 JP JP2025130097A patent/JP2025160458A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510733A5 (OSRAM) | ||
| JP2016537383A5 (OSRAM) | ||
| JP2018508483A5 (OSRAM) | ||
| PH12019502785A1 (en) | Anti trbc1 antigen binding domains | |
| IL299221A (en) | CD3 binding antibodies | |
| JP2017535257A5 (OSRAM) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| JP2018532383A5 (OSRAM) | ||
| IL253462B (en) | Treatment of cancer with anti-lap monoclonal antibodies | |
| JP2014522850A5 (OSRAM) | ||
| HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
| JP2018520657A5 (OSRAM) | ||
| JP2018505674A5 (OSRAM) | ||
| JP2018515474A5 (OSRAM) | ||
| JP2014526898A5 (OSRAM) | ||
| MY200988A (en) | CD3 Binding Antibodies | |
| JP2017524715A5 (OSRAM) | ||
| JP2018512138A5 (OSRAM) | ||
| RU2016124540A (ru) | Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака | |
| JP2017048240A5 (OSRAM) | ||
| JP2019535670A5 (OSRAM) | ||
| JP2017500057A5 (OSRAM) | ||
| JP2009225799A5 (OSRAM) | ||
| MY190771A (en) | Anti-pd-l1 antibodies and uses thereof |